ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	Recruiting	Phase 1 / Phase 2	2026-01-07		NCT05405595

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Adagene Inc	6
Merck Sharp & Dohme LLC	650

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Asan Medical Center	Seoul	South Korea	338
CHA Bundang Medical Center, CHA university	Seongnam	South Korea	1
Chungbuk National University Hospital	Cheongju-si	South Korea	20
City of Hope National Medical Center	Duarte	United States	68
City of Hope Orange County	Irvine	United States	1
Dong -A University Hospital	Seogu	South Korea	1
Florida cancer specialist/Sarah Cannon Research Institute	Sarasota	United States	1
Fred Hutchinson Cancer Center	Seattle	United States	250
Fujian Cancer Hospital	Fuzhou	China	55
Hong Kong Humanity & Health Clinical Trial Center	Hong Kong	China	1
Honor Health Research Institute	Scottsdale	United States	1
KangBuk Samsung Hospital	Seoul	South Korea	1
Keimyung University Dongsan Hospital	Daegu	South Korea	2
MD Anderson Cancer Center	Houston	United States	589
Prince of Wales Hospital	Hong Kong	China	3
Samsung Medical Center	Seoul	South Korea	7
Seoul National University Hospital	Seoul	South Korea	393
Severance Hospital Yonsei University Health System	Seoul	South Korea	2
SunYat-sen University Cancer Center	Guangzhou	China	4
The Catholic University of Korea Street. Vincent Hospital	Suwon	South Korea	1
The Cleveland Clinic	Cleveland	United States	1

Clinical trials